Role of proteomics in biomarker discovery: Prognosis and diagnosis of neuropsychiatric disorders

Advances in Protein Chemistry and Structural Biology

Volumn 94, Issue , 2014, Pages 39-75

  Patel, Suman ^a  

^a INDIAN NATIONAL SCIENCE ACADEMY   (India)

Author keywords

Alzheimer's disease; Anxiety and depression; Biomarker; Bipolar disorder; Blood; Cerebrospinal fluid; Extracellular fluid serum; Proteomics; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; BIPOLAR DISORDER; CHEMICAL LABELING; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; PROTEOMICS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; MENTAL DISORDERS; METABOLISM;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MENTAL DISORDERS; PROGNOSIS; PROTEOMICS;

EID: 84896260225     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800168-4.00003-2     Document Type: Chapter

References (133)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimer's Disease 2006, 9:293-348.
2. Albertini V., Benussi L., Paterlini A., Glionna M., Prestia A., Bocchio-Chiavetto L., et al. Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. Electrophoresis 2012, 33(24):3738-3744.
3. Anderson N.L., Anderson N.G. Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis 1998, 19(11):1853-1861.
4. Ando K., Dourlen P., Sambo A.V., Bretteville A., Bélarbi K., Vingtdeux V., et al. Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging 2013, 34(3):757-769.
5. Bachi A., Bonaldi T. Quantitative proteomics as a new piece of the systems biology puzzle. Journal of Proteomics 2008, 71:357-367.
6. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews. Neuroscience 2007, 8:663-672.
7. Bazenet C., Lovestone S. Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Neurobiology of Aging 2012, 6(4):441-454.
8. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 2006, 6(11):3414-3425.
9. Benazzi F. Bipolar II disorder: Epidemiology, diagnosis and management. CNS Drugs 2007, 21(9):727-740.
10. Bola J., Kao D., Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database of Systematic Reviews 2011, 6. CD006374.
11. Burns J.K. An evolutionary theory of schizophrenia: Cortical connectivity, metarepresentation, and the social brain. The Behavioral and Brain Sciences 2004, 27(6):831-885.
12. Bush G., Luu P., Posner M.I. Cognitive and emotional influences in anterior cingulate cortex. Trends in Cognitive Sciences 2000, 4(6):215-222.
13. Butterfield D.A., Dalle-Donne I. Redox proteomics. Antioxidants & Redox Signaling 2012, 17(11):1487-1489.
14. Bystritsky A. Treatment-resistant anxiety disorders. Molecular Psychiatry 2006, 11:805-814.
15. Carrette O., Burkhard P.R., Hughes S., Hochstrasser D.F., Sanchez J.C. Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process?. Proteomics 2005, 5:3060-3065.
16. Castaño E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurological Research 2006, 28(2):155-163.
17. Chakravarty, A. (2003). Surrogate markers: Their role in regulatory decision process. Food and Drug Administration. http://www.fda.gov/cder/Offices/Biostatistics/Chakravarty_376/sld016.htm.
18. Chakravarty S., Reddy B.R., Sudhakar S.R., Saxena S., Das T., Meghah V., et al. Chronic unpredictable stress (CUS)-induced anxiety and related mood disorders in a zebrafish model: Altered brain proteome profile implicates mitochondrial dysfunction. PLoS One 2013, 8(5):e63302.
19. Chan S.W., Hsiung P.C., Thompson D.R., Chen S.C., Hwu H.G. Health-related quality of life of Chinese people with schizophrenia in Hong Kong and Taipei: A cross-sectional analysis. Research in Nursing & Health 2007, 30:261-269.
20. Chan M.K., Tsang T.M., Harris L.W., Guest P.C., Holmes E., Bahn S. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Molecular Psychiatry 2011, 16(12):1189-1202.
21. Chandramouli Kondethimmanahalli, Qian Pei-Yuan Proteomics: Challenges, techniques and possibilities to overcome biological sample complexity. Human Genomics and Proteomics 2009, 2009:239204.
22. Chen X., Smith L.M., Bradbury M.E. Site-specific mass tagging with stable isotopes in proteins for accurate and efficient protein identification. Analytical Chemistry 2000, 72:1134.
23. Cheon M.S., Kim S.H., Fountoulakis M., Lubec G. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. Journal of Neural Transmission. Supplementum 2003, (67):225-234.
24. Chuang C.C., Nakagome K., Pu S., Lan T.H., Lee C.Y., Sun C.W. Discriminant analysis of functional optical topography for schizophrenia diagnosis. Journal of Biomedical Optics 2014, 19(1):11006.
25. Cocciolo A., Di Domenico F., Coccia R., Fiorini A., Cai J., Pierce W.M., et al. Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radical Biology & Medicine 2012, 53(10):1868-1876.
26. Craft G.E., Chen A., Nairn A.C. Recent advances in quantitative neuroproteomics. Methods 2013, 61(3):186-218.
27. Davidsson P., Folkesson S., Christiansson M., Lindbjer M., Dellheden B., Blennow K., et al. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Communications in Mass Spectrometry 2002, 16(22):2083-2088.
28. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine 2000, 160:2101-2107.
29. Ditzen C., Varadarajulu J., Czibere L., Gonik M., Targosz B.S., Hambsch B., et al. Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Molecular Psychiatry 2010, 15(7):702-711.
30. Donovan L.E., Higginbotham L., Dammer E.B., Gearing M., Rees H.D., Xia Q., et al. Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. Proteomics. Clinical Applications 2012, 6(3-4):201-211.
31. Dubois B., Epelbaum S., Santos A., Di Stefano F., Julian A., Michon A., et al. Alzheimer disease: From biomarkers to diagnosis. Revue Neurologique (Paris) 2013, 169(10):744-751.
32. Dunbar R.I.M. The social brain hypothesis. Evolutionary Anthropology 1998, 6(5):178-190.
33. Emmett M.R., Kroes R.A., Moskal J.R., Conrad C.A., Priebe W., Laezza F., et al. Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology 2013, 39(1):5-23.
34. Ernoult E., Bourreau A., Gamelin E., Guette C. A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. Journal of Biomedicine & Biotechnology 2010, 2010:927917.
35. Fabbri C., Di Girolamo G., Serretti A. Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2013, 162(6):487-520.
36. Filiou M.D., Turck C.W., Martins-de-Souza D. Quantitative proteomics for investigating psychiatric disorders. Proteomics. Clinical Applications 2011, 5(1-2):38-49.
37. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Annals of Neurology 2007, 61(2):120-129.
38. Föcking M., Dicker P., English J.A., Schubert K.O., Dunn M.J., Cotter D.R. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Archives of General Psychiatry 2011, 68(5):477-488.
39. Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nature Medicine 2004, 10(10):1055-1063.
40. Frank E., Kessler M.S., Filiou M.D., Zhang Y., Maccarrone G., Reckow S., et al. Stable isotope metabolic labeling with a novel 15N-enriched bacteria diet for improved proteomic analyses of mouse models for psychopathologies. PLoS One 2009, 4(11):e7821.
41. Freedman R. Schizophrenia. The New England Journal of Medicine 2003, 349:1738-1749.
42. Friedman D.B. Quantitative proteomics for two-dimensional gels using difference gel electrophoresis. Methods in Molecular Biology 2007, 367:219-239.
43. Friedman D.B., Hill S., Keller J.W., Merchant N.B., Levy S.E., Coffey R.J., et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4(3):793-811.
44. Frisoni G.B., Bocchetta M., Chételat G., Rabinovici G.D., de Leon M.J., Kaye J., et al. Imaging markers for Alzheimer disease: Which vs how. Neurology 2013, 81(5):487-500.
45. Gokhale A., Larimore J., Werner E., So L., Moreno-De-Luca A., Lese-Martin C., et al. Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1. The Journal of Neuroscience 2012, 32(11):3697-3711.
46. Golab J., Bauer T.M., Daniel V., Naujokat C. Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. Clinica Chimica Acta 2004, 340:27-40.
47. Guest P.C., Urday S., Ma D., Stelzhammer V., Harris L.W., Amess B., et al. Proteomic analysis of the maternal protein restriction rat model for schizophrenia: Identification of translational changes in hormonal signaling pathways and glutamate neurotransmission. Proteomics 2012, 12(23-24):3580-3589.
48. Guo L.H., Alexopoulos P., Wagenpfeil S., Kurz A., Perneczky R. Plasma proteomics for the identification of Alzheimer disease. Alzheimer Disease and Associated Disorders 2013, 27(4):337-342.
49. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology 1999, 17(10):994-999.
50. Harsha H.C., Molina H., Pandey A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nature Protocols 2008, 3(3):505-516.
51. Henkel A.W., Müller K., Lewczuk P., Müller T., Marcus K., Kornhuber J., et al. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: A pilot study. Journal of Neural Transmission 2012, 119(7):779-788.
52. Henninger N., Feldmann R.E., Fütterer C.D., Schrempp C., Maurer M.H., Waschke K.F., et al. Spatial learning induces predominant downregulation of cytosolic proteins in the rat hippocampus. Genes, Brain, and Behavior 2007, 6(2):128-140.
53. Herberth M., Koethe D., Levin Y., Schwarz E., Krzyszton N.D., Schoeffmann S., et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011, 11(1):94-105.
54. Hu Y., Hosseini A., Kauwe J.S., Gross J., Cairns N.J., Goate A.M., et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics. Clinical Applications 2007, 11:1373-1384.
55. Huang J.T., Wang L., Prabakaran S., Wengenroth M., Lockstone H.E., Koethe D., et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Molecular Psychiatry 2008, 13(12):1118-1128.
56. Hünnerkopf R., Grassl J., Thome J. Proteomics: Biomarker research in psychiatry. Fortschritte der Neurologie-Psychiatrie 2007, 75(10):579-586.
57. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
58. Ionescu D.F., Niciu M.J., Henter I.D., Zarate C.A. Defining anxious depression: A review of the literature. CNS Spectrums 2013, 18(5):252-260.
59. Jellema T., Baker C.I., Wicker B., Perrett D.I. Neural representation for the perception of the intentionality of actions. Brain and Cognition 2000, 44(2):280-302.
60. Jimenez C.R., El Filali Z., Knol J.C., Hoekman K., Kruyt F.A., Giaccone G., et al. Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics. Clinical Applications 2007, 1(6):598-604.
61. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Molecular Psychiatry 2000, 5(2):142-149.
62. Jungblut P.R., Holzhütter H.G., Apweiler R., Schlüter H. The speciation of the proteome. Chemistry Central Journal 2008, 2:16.
63. Keller M.B., Hanks D.L. Anxiety symptom relief in depression treatment outcomes. The Journal of Clinical Psychiatry 1995, 56(Suppl. 6):22-29.
64. Khawaja X., Xu J., Liang J.J., Barrett J.E. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. Journal of Neuroscience Research 2004, 75(4):451-460.
65. Kim H.J., Eom C.Y., Kwon J., Joo J., Lee S., Nah S.S., et al. Roles of interferon-gamma and its target genes in schizophrenia: Proteomics-based reverse genetics from mouse to human. Proteomics 2012, 12(11):1815-1829.
66. Kim H.G., Kim K.L. Decreased hippocampal cholinergic neurostimulating peptide precursor protein associated with stress exposure in rat brain by proteomic analysis. Journal of Neuroscience Research 2007, 85(13):2898-2908.
67. Krömer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. The Journal of Neuroscience 2005, 25(17):4375-4384.
68. Lehmann S., Delaby C., Touchon J., Hirtz C., Gabelle A. Biomarkers of Alzheimer's disease: The present and the future. Revue Neurologique (Paris) 2013, 169(10):719-723.
69. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F.M., Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Molecular Psychiatry 2010, 15(11):1088-1100.
70. Li X., Song X.Q., Gao J.S., Pang L.J., Li Y.H., Hao Y.H., et al. Proteomic analysis of novel serum markers in first-episode schizophrenics before versus after treatment of risperidone. Zhonghua Yi Xue Za Zhi 2012, 92(45):3194-3198.
71. Liao L.J., Park S.K., Xu T., Vanderklish P., Yates J.R. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:15281-15286.
72. Mairesse J., Vercoutter-Edouart A.S., Marrocco J., Zuena A.R., Giovine A., Nicoletti F., et al. Proteomic characterization in the hippocampus of prenatally stressed rats. Journal of Proteomics 2012, 75(6):1764-1770.
73. Manral P., Sharma P., Hariprasad G., Chandralekha Tripathi M., Srinivasan A. Can apolipoproteins and complement factors be biomarkers of Alzheimer's disease?. Current Alzheimer Research 2012, 9(8):935-943.
74. Martins-de-Souza D. Proteomics as a tool for understanding schizophrenia. Clinical Psychopharmacology and Neuroscience 2011, 9(3):95-101.
75. Martins-de-Souza D., Dias-Neto E., Schmitt A., Falkai P., Gormanns P., Maccarrone G., et al. Proteome analysis of schizophrenia brain tissue. The World Journal of Biological Psychiatry 2010, 2:110-120.
76. Martins-de-Souza D., Guest P.C., Harris L.W., Vanattou-Saifoudine N., Webster M.J., Rahmoune H., et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Translational Psychiatry 2012, 2:e87.
77. Martins-de-Souza D., Guest P.C., Rahmoune H., Bahn S. Proteomic approaches to unravel the complexity of schizophrenia. Expert Review of Proteomics 2012, 9(1):97-108.
78. Martins-de-Souza D., Harris L.W., Guest P.C., Turck C.W., Bahn S. The role of proteomics in depression research. European Archives of Psychiatry and Clinical Neuroscience 2010, 260(6):499-506.
79. Matar H.E., Almerie M.Q., Sampson S. Fluphenazine (oral) versus placebo for schizophrenia. Schizophrenia Bulletin 2013, 39(6):1187-1188.
80. Mattsson N., Rosén E., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012, 78(7):468-476.
81. Maurer M.H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrometry Reviews 2010, 29(1):17-28.
82. Mechref Y., Madera M., Novotny M.V. Glycoprotein enrichment through lectin affinity techniques. Methods in Molecular Biology 2008, 424:373-396.
83. Mitchell P.B. Bipolar disorder. Australian Family Physician 2013, 42(9):616-619.
84. Nakagawa N., Yao H., Nakahara T., Inomata S., Hashimoto K., Kuroki T. Serum of transthyretin as a treatment-responsive biomarker for schizophrenia. Brain and Nerve 2013, 65(9):1093-1099.
85. Novikova S.I., He F., Cutrufello N.J., Lidow M.S. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiology of Disease 2006, 23(1):61-76.
86. Oda Y., Huang K., Cross F.R., Cowburn D., Chait B.T. Accurate quantitation of protein expression and site-specific phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:6591.
87. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular and Cellular Proteomics 2002, 1:376-386.
88. Pacchiarotti I., Bond D.J., Baldessarini R.J., Nolen W.A., Grunze H., Licht R.W., et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. The American Journal of Psychiatry 2013, 170(11):1249-1262.
89. Paulson L., Martin P., Persson A., Nilsson C.L., Ljung E., Westman-Brinkmalm A., et al. Comparative genome and proteome analysis of cerebral cortex from MK-801-treated rats. Journal of Neuroscience Research 2003, 71:526-533.
90. Pennington K., Beasley C.L., Dicker P., Fagan A., English J., Pariante C.M., et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Molecular Psychiatry 2008, 13(12):1102-1117.
91. Perneczky R., Guo L.H., Kagerbauer S.M., Werle L., Kurz A., Martin J., et al. Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease. Translational Psychiatry 2013, 3:e227.
92. Pich E.M., Vargas G., Domenici E. Biomarkers for antipsychotic therapies. Handbook of Experimental Pharmacology 2012, 212:339-360.
93. Pitchot W., Scantamburlo G., Ansseau M. Clinical and therapeutical approach of depression in old age. Revue Médicale de Li[U+0450]ge 2012, 67(11):566-572.
94. Postmes L., Sno H.N., Goedhart S., van der Stel J., Heering H.D., de Haan L. Schizophrenia as a self-disorder due to perceptual incoherence. Schizophrenia Research 2014, 152(1):41-50.
95. Prabakaran S., Wengenroth M., Lockstone H.E., Lilley K., Leweke F.M., Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. Journal of Proteome Research 2007, 6(1):141-149.
96. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Research. Molecular Brain Research 2003, 118(1-2):140-146.
97. Rao S., Zisook S. Anxious depression: Clinical features and treatment. Current Psychiatry Reports 2009, 11:429-436.
98. Robillard R., Naismith S.L., Hickie I.B. Recent advances in sleep-wake cycle and biological rhythms in bipolar disorder. Current Psychiatry Reports 2013, 15(10):402.
99. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular & Cellular Proteomics 2004, 3:1154-1169.
100. Rush A.J. The varied clinical presentations of major depressive disorder. The Journal of Clinical Psychiatry 2007, 68:4-10.
101. Said M.A., Hatim A., Habil M.H., Zafidah W., Haslina M.Y., Badiah Y., et al. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Preventive Medicine 2013, 57(Suppl):S50-S53.
102. Schneider G., Heuft G. Anxiety and depression in the elderly. Zeitschrift für Psychosomatische Medizin und Psychotherapie 2012, 58(4):336-356.
103. Shi M., Caudle W.M., Zhang J. Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiology of Disease 2009, 35(2):157-164.
104. Shi M., Hwang H., Zhang J. Quantitative characterization of glycoproteins in neurodegenerative disorders using iTRAQ. Methods in Molecular Biology 2013, 951:279-296.
105. Shiozaki A., Tsuji T., Kohno R., Kawamata J., Uemura K., Teraoka H., et al. Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation. Journal of Alzheimer's Disease 2004, 6(3):257-268.
106. Sibille E., French B. Biological substrates underpinning diagnosis of major depression. The International Journal of Neuropsychopharmacology 2013, 16(8):1893-1909.
107. Sikich Linmarie Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents. Child and Adolescent Psychiatric Clinics of North America 2013, 22:655-673.
108. Singh I., Rose N. Biomarkers in psychiatry. Nature 2009, 460(7252):202-207.
109. Skovronsky D.M., Lee V.M., Trojanowski J.Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annual Review of Pathology 2006, 1:151-170.
110. Soares H.D., Potter W.Z., Pickering E., Kuhn M., Immermann F.W., Shera D.M., et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Archives of Neurology 2012, 69(10):1310-1317.
111. Sokolowska E., Hovatta I. Anxiety genetics-Findings from cross-species genome-wide approaches. Biology of Mood and Anxiety Disorders 2013, 3(1):3-9.
112. Spellman D.S., Deinhardt K., Darie C.C., Chao M.V., Neubert T.A. Stable isotopic labeling by amino acids in cultured primary neurons. Molecular & Cellular Proteomics 2008, 7:1067-1076.
113. Squassina A., Manchia M., Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Human Genomics and Proteomics 2010, 2010:159761.
114. Sultana R., Baglioni M., Cecchetti R., Cai J., Klein J.B., Bastiani P., et al. Lymphocyte mitochondria: Toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radical Biology & Medicine 2013, 65C:595-606.
115. Sultana R., Boyd-Kimball D., Cai J., Pierce W.M., Klein J.B., Merchant M., et al. Proteomics analysis of the Alzheimer's disease hippocampal proteome. Journal of Alzheimer's Disease 2007, 11(2):153-164.
116. Sussulini A., Dihazi H., Banzato C.E., Arruda M.A., Stühmer W., Ehrenreich H., et al. Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder. Proteomics 2011, 11(2):261-269.
117. Suzuki H., Inoue Y., Gen K. A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. Therapeutic Advances in Psychopharmacology 2012, 2(6):227-234.
118. Szego E.M., Janáky T., Szabó Z., Csorba A., Kompagne H., Müller G., et al. A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome. European Neuropsychopharmacology 2010, 20(2):96-111.
119. Thongboonkerd V. Proteomics. Forum of Nutrition 2007, 60:80-90.
120. Tonack S., Aspinall-O'Dea M., Jenkins R.E., Elliot V., Murray S., Lane C.S., et al. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. Journal of Proteomics 2009, 73:352-356.
121. Vercauteren F.G., Flores G., Ma W., Chabot J.G., Geenen L., Clerens S., et al. An organelle proteomic method to study neurotransmission-related proteins, applied to a neurodevelopmental model of schizophrenia. Proteomics 2007, 7(19):3569-3579.
122. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320(25):539-543.
123. Wijte D., McDonnell L.A., Balog C.I., Bossers K., Deelder A.M., Swaab D.F., et al. A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. Methods 2012, 56(4):500-507.
124. Wilkins M.R., Pasquali C., Appel R.D., Ou K., Golaz O., Sanchez J.C., et al. From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (New York) 1996, 14:61-65.
125. Woods A.G., Sokolowska I., Taurines R., Gerlach M., Dudley E., Thome J., et al. Potential biomarkers in psychiatry: Focus on the cholesterol system. Journal of Cellular and Molecular Medicine 2012, 16(6):1184-1195.
126. Xiao Z., Prieto D., Conrads T.P., Veenstra T.D., Issaq H.J. Proteomic patterns: Their potential for disease diagnosis. Molecular and Cellular Endocrinology 2005, 230(1-2):95-106.
127. Yang M.H., Yang Y.H., Lu C.Y., Jong S.B., Chen L.J., Lin Y.F., et al. Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. Journal of Proteomics 2012, 75(12):3617-3629.
128. Yang Y., Yang D., Tang G., Zhou C., Cheng K., Zhou J., et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience 2013, 247:191-200.
129. Yuan X., Desiderio D.M. Human cerebrospinal fluid peptidomics. Journal of Mass Spectrometry 2005, 40:176-181.
130. Zellner M., Veitinger M., Umlauf E. The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathologica 2009, 118(1):181-195.
131. Zhang Y., Filiou M.D., Reckow S., Gormanns P., Maccarrone G., Kessler M.S., et al. Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Molecular & Cellular Proteomics 2011, 10(12). M111.008110.
132. Zhang J., Goodlett D.R., Quinn J.F., Peskind E., Kaye J.A., Zhou Y., et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease 2005, 7(2):125-133.
133. Zhang K., Schrag M., Crofton A., Trivedi R., Vinters H., Kirsch W. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012, 12(8):1261-1268.